Table 2.

Multivariable model for persistence

	Point estimate	Lower 95% CI	Upper 95% CI	P values
ER	0.8	0.55	1.18	0.27
500 mg or less	ref
500–1500 mg	1.66	1.13	2.44	0.01
>1500 mg	2.24	1.02	4.73	0.04
HbA1c increase 1%	0.73	0.59	0.88	<0.01
Age 50–65	1.02	0.66	1.57	0.94
Age≥65	1.06	0.65	1.72	0.82
Male	0.74	0.49	1.13	0.17
White	ref
Black	0.53	0.32	0.86	0.01
Asian	0.41	0.17	0.9	0.04
Other	0.78	0.53	1.16	0.22
Statin	0.62	0.41	0.93	0.02
Antihypertensive	0.96	0.64	1.42	0.83
Endocrine clinic	0.62	0.4	0.96	0.03
OCT-1 inhibitor use	0.89	0.52	1.48	0.67
Diabetes diagnosis	0.38	0.19	0.75	0.01
Diabetes complications	0.52	0.33	0.79	<0.01
Heart failure	1.43	0.6	3.13	0.39
Hypothyroidism	0.96	0.63	1.44	0.84
Renal disease	1.59	0.76	3.15	0.20
Liver disease	0.54	0.23	1.12	0.12
Obesity	0.58	0.41	0.83	<0.01
Depression	0.7	0.44	1.11	0.14

ER, extended release; HbA1c, haemoglobin A1c; OCT-1, organic cation transport 1.